SEARCH

SEARCH BY CITATION

References

  • 1
    Carvalho ACA. Hemostasis and thrombosis, In: SchiffmanFJ. ed. Hematologic Pathophysiology. Philadelphia: Lippincott-Raven; 1998, pp. 161244.
  • 2
    Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Ann Rev Med 1995; 46: 103112.
  • 3
    Hack CE. Tissue factor pathway of coagulation in sepsis. Crit Care Med 2000; 28 (9 Suppl): S25S30.
  • 4
    Levi M, Keller TT, Van Gorp E, et al. Infection and inflammation and the coagulation system. Cardiovasc Res 2003; 60 (1): 2639.
  • 5
    Blanchette VS, Sparling C, Turner C. Inherited bleeding disorders. Baillieres Clin Haematol 1991; 4 (2): 291332.
  • 6
    Mann KG. Thrombin formation. Chest 2003; 124 (3 Suppl): 4S10S.
  • 7
    Doshi SN, Marmur JD. Evolving role of tissue factor and its pathway inhibitor. Crit Care Med 2002; 30 (5 Suppl): S241S250.
  • 8
    Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003; 31 (4): 12501256.
  • 9
    Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29 (7): 13031310.
  • 10
    De Laforcade AM, Freeman LM, Shaw SP, et al. Hemostatic changes in dogs with naturally occurring sepsis. J Vet Intern Med 2003; 17: 674679.
  • 11
    Brady CA, Otto CM, Van Winkle TJ, et al. Severe sepsis in cats: 29 cases (1986-1998). J Am Vet Med Assoc 2000; 217 (4): 531535.
  • 12
    Lanz OI, Ellison GW, Bellah JR, et al. Surgical treatment of septic peritonitis without abdominal drainage in 28 dogs. J Am Anim Hosp Assoc 2001; 37 (1): 8792.
  • 13
    Hambleton J, Leung LL, Levi M. Coagulation: consultative hemostasis. Hematology 2002; 335352.
  • 14
    Levi M. Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient. J Crit Care 2001; 16 (4): 167177.
  • 15
    Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001; 29 (7 Suppl): S99S106.
  • 16
    Di Cera E. Thrombin interactions. Chest 2003; 124 (3 Suppl): 11S17S.
  • 17
    Levi M, Ten Cate H, Van Der Poll T. Endothelium: interface between coagulation and inflammation. Crit Care Med 2002; 30 (5 Suppl): S220S224.
  • 18
    Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344 (10): 699709.
  • 19
    Levi M, De Jonge E, Van Der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001; 29 (7 Suppl): S90S94.
  • 20
    Golino P. The inhibitors of the tissue factor: factor VII pathway. Thromb Res 2002; 106: V257V265.
  • 21
    Ten Cate H. Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med 2000; 28 (9 Suppl): S9S11.
  • 22
    Edgington TS, Mackman N, Brand K, et al. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66 (1): 6779.
  • 23
    Camerer E, Kolsto A, Prydz H. Cell biology of tissue factor, the principle initiator of blood coagulation. Thromb Res 1996; 81 (1): 141.
  • 24
    Drake TA, Cheng J, Chang A, et al. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol 1993; 142 (5): 14581470.
  • 25
    Rauch U, Nemerson Y. Circulating tissue factor and thrombosis. Curr Opin Hematol 2000; 7 (5): 273277.
  • 26
    Nieuwland R, Berckmans RJ, McGregor S, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95 (3): 930935.
  • 27
    Wolberg AS, Kon RH, Monroe DM, et al. Deencryption of cellular tissue factor is independent of its cytoplasmic domain. Biochem Biophys Res Commun 2000; 272 (2): 332336.
  • 28
    Conkling PR, Greenberg CS, Weinberg JB. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 1988; 72 (1): 128133.
  • 29
    Conway EM, Bach R, Rosenberg RD, et al. Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res 1989; 53 (3): 231241.
  • 30
    Warr TA, Rao LV, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75 (7): 14811489.
  • 31
    Taylor FB Jr., Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33 (3): 127134.
  • 32
    Gando S, Nanzaki S, Sasaki S, et al. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost 1998; 79 (6): 11111115.
  • 33
    Leatham EW, Bath PM, Tooze JA, et al. Increased monocyte tissue factor expression in coronary disease. Br Heart J 1995; 73 (1): 1013.
  • 34
    Belting M, Dorrell MI, Sandgren S, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004; 10 (5): 502509.
  • 35
    Versteeg HH, Peppelenbosch MP, Spek CA. Tissue factor signal transduction in angiogenesis. Carcinogenesis 2003; 24 (6): 10091013.
  • 36
    Bugge TH, Xiao Q, Kombrinck KW, et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci USA 1996; 93 (13): 62586263.
  • 37
    Peppelenbosch MP, Versteeg HH. Cell biology of tissue factor, an unusual member of the cytokine receptor family. Trends Cardiovasc Med 2001; 11 (8): 335339.
  • 38
    Osterud B, Bajaj MS, Bajaj SP. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 73 (5): 873875.
  • 39
    Li Y, Rodriquez M, Spencer FA, et al. Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance. J Thromb Thrombolysis 2002; 14 (2): 123129.
  • 40
    Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991; 66 (1): 615.
  • 41
    Gando S, Nanzaki S, Morimoto Y, et al. Tissue factor pathway inhibitor response does not correlate with tissue factor-induced disseminated intravascular coagulation and multiple organ dysfunction syndrome in trauma patients. Crit Care Med 2001; 29 (2): 262266.
  • 42
    Asakura H, Ontachi Y, Mizutani T, et al. Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases. Blood Coag Fibrinolysis 2001; 12 (1): 18.
  • 43
    Novotny WF, Brown SG, Miletich JP, et al. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78 (2): 387393.
  • 44
    Gando S, Kameue T, Morimoto Y, et al. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002; 30 (8): 17291734.
  • 45
    Gando S, Kameue T, Matsuda N, et al. Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients. Thromb Res 2003; 109 (2): 119124.
  • 46
    Matyal R, Vin Y, Delude RL, et al. Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock. Intensive Care Med 2001; 27 (8): 12741280.
  • 47
    Carr C, Bild GS, Chang AC, et al. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 1994; 44 (3): 126137.
  • 48
    Creasey AA, Chang AC, Feigen L, et al. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91 (6): 28502860.
  • 49
    Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. J Am Med Assoc 2003; 290 (2): 238247.
  • 50
    Roemisch J, Gray E, Hoffmann JN, et al. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coag Fibrinolysis 2002; 13 (8): 657670.
  • 51
    Opal SM, Kessler CM, Roemisch J, et al. Antithrombin, heparin, and heparan sulfate. Crit Care Med 2002; 30 (5 Suppl): S325S331.
  • 52
    Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119 (1 Suppl): 64S94S.
  • 53
    Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337 (10): 688698.
  • 54
    Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130 (10): 800809.
  • 55
    Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004; 140 (3): 175183.
  • 56
    Goodman JS, Rozanski EA, Brown D, et al. The effects of low-molecular weight heparin on hematologic and coagulation parameters in normal cats [abstract]. In: Proceedings of the 17th Annual American College of Internal Medicine Forum 1999, p. 268.
  • 57
    Mischke R, Grebe S, Jacobs C, et al. Amidolytic heparin activity and values for several hemostatic variables after repeated subcutaneous administration of high doses of a low molecular weight heparin in healthy dogs. Am J Vet Res 2001; 62 (4): 595598.
  • 58
    Mischke RH, Schuttert C, Grebe SI. Anticoagulant effects of repeated subcutaneous injections of high doses of unfractionated heparin in healthy dogs. Am J Vet Res 2001; 62 (12): 18871891.
  • 59
    Schwarzwald CC, Feige K, Wunderli-Allenspach H, et al. Comparison of pharmacokinetic variables for two low-molecular-weight heparins after subcutaneous administration of a single dose to horses. Am J Vet Res 2002; 63 (6): 868873.
  • 60
    Leadley RJ Jr., Kasiewski CJ, Bostwick JS, et al. Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin. Arterioscler Thromb Vasc Biol 1998; 18 (6): 908914.
  • 61
    Mischke R, Grebe S. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin. Res Vet Sci 2000; 69 (3): 241247.
  • 62
    Morris TA, Marsh JJ, Konopka R, et al. Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thrombo-embolism. Thromb Res 2000; 100 (3): 185194.
  • 63
    Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000; 26 (Suppl 1): 3138.
  • 64
    Totzke G, Schobersberger W, Schloesser M, et al. Effects of antithrombin III on tumor necrosis factor-alpha and interleukin-1beta synthesis in vascular smooth muscle cells. J Interferon Cytokine Res 2001; 21 (12): 10631069.
  • 65
    Uchiba M, Okajima K, Murakami K. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res 1998; 89 (5): 233241.
  • 66
    Souter PJ, Thomas S, Hubbard AR, et al. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 2001; 29 (1): 134139.
  • 67
    Hoffmann JN, Vollmar B, Laschke MW, et al. Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 2002; 88 (2): 242252.
  • 68
    Pulletz S, Lehmann C, Volk T, et al. Influence of heparin and hirudin on endothelial binding of antithrombin in experimental thrombinemia. Crit Care Med 2000; 28 (8): 28812886.
  • 69
    Barton MH, Morris DD, Norton N, et al. Hemostatic and fibrinolytic indices in neonatal foals with presumed septicemia. J Vet Intern Med 1998; 12: 2635.
  • 70
    Lorente JA, Garcia-Frade LJ, Landin L, et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993; 103 (5): 15361542.
  • 71
    Dickneite G. Antithrombin III in animal models of sepsis and organ failure. Semin Thromb Hemost 1998; 24 (1): 6169.
  • 72
    Taylor FB Jr., Emerson TE, Jordan R Jr., et al. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988; 26 (3): 227235.
  • 73
    Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. J Am Med Assoc 2001; 286 (15): 18691878.
  • 74
    Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32 (3): 858873.
  • 75
    Xu J, Esmon NL, Esmon CT. Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation. J Biol Chem 1999; 274 (10): 67046710.
  • 76
    Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001; 29 (7 Suppl): S48S51.
  • 77
    Taylor FB Jr., Peer GT, Lockhart MS, et al. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001; 97 (6): 16851688.
  • 78
    Esmon CT. The protein C pathway. Chest 2003; 124 (3 Suppl): 26S32S.
  • 79
    Faust SN, Heyderman RS, Levin M. Coagulation in severe sepsis: a central role for thrombomodulin and activated protein C. Crit Care Med 2001; 29 (7 Suppl): S62S67.
  • 80
    Griffin JH. Blood coagulation. The thrombin paradox. Nature 1995; 378 (6555): 337338.
  • 81
    Dreyfus M, Magny JF, Bridey F, et al. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991; 325 (22): 15651568.
  • 82
    Esmon CT. The endothelial cell protein C receptor. Thromb Haemost 2000; 83 (5): 639643.
  • 83
    Cheng T, Liu D, Griffin JH, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003; 9 (3): 338342.
  • 84
    Murakami K, Okajima K, Uchiba M, et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997; 272 (2 Part 1): L197L202.
  • 85
    White B, Schmidt M, Murphy C, et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappa B (NF-kappa B) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 2000; 110 (1): 130134.
  • 86
    Collen D. Ham–Wasserman lecture: role of the plasminogen system in fibrin-homeostasis and tissue remodeling. Hematology (Am Soc Hematol Educ Prog) 2001; 19.
  • 87
    De Fouw NJ, De Jong YF, Haverkate F, et al. Activated protein C increases fibrin clot lysis by neutralization of plasminogen activator inhibitor – no evidence for a cofactor role of protein S. Thromb Haemost 1988; 60 (2): 328333.
  • 88
    Fisher CJ Jr., Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000; 28 (9 Suppl): S49S56.
  • 89
    Kinasewitz GT, Yan SB, Basson B, et al. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism. Crit Care 2004; 8 (2): R82R90.
  • 90
    Opal SM. Clinical impact of novel anticoagulation strategies in sepsis. Curr Opin Crit Care 2001; 7 (5): 347353.
  • 91
    Jackson CV, Bailey BD, Shetler TJ. Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 2000; 295 (3): 967971.
  • 92
    Nesheim M. Thrombin and fibrinolysis. Chest 2003; 124 (3 Suppl): 33S39S.
  • 93
    Ariens RA, Lai TS, Weisel JW, et al. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 2002; 100 (3): 743754.
  • 94
    Hack CE. Fibrinolysis in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27 (6): 633638.
  • 95
    Green J, Doughty L, Kaplan SS, et al. The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure. Thromb Haemost 2002; 87 (2): 218223.
  • 96
    Pralong G, Calandra T, Glauser MP, et al. Plasminogen activator inhibitor: 1: a new prognostic marker in septic shock. Thromb Haemost 1989; 61 (3): 459462.
  • 97
    Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin–thrombomodulin complex. J Biol Chem 1996; 271 (28): 1660316608.
  • 98
    Mao SS, Cooper CM, Wood T, et al. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J Biol Chem 1999; 274 (49): 3504635052.